More evidence for antiplatelet therapy in stenting
This article was originally published in Clinica
Executive Summary
Ticlopidine antiplatelet therapy cut the risk of heart attack by 82% in ISAR, the German Intracoronary Stenting and Antithrombotic Regimen trial. The results, published in the New England Journal of Medicine (April 25th) add weight to the growing case for antiplatelet therapy instead of anticoagulants after stenting.